Xiaflex

Drug Overview

Dealing with reproductive health conditions can be physically and emotionally challenging. Within the specialized Drug Category of Urology, treatments that directly address structural abnormalities of the male reproductive system offer hope and restored function. Xiaflex is a highly specialized medication designed to treat conditions involving abnormal collagen buildup, specifically Peyronie’s disease.

Xiaflex belongs to a unique Drug Class known as Enzymes (Proteolytic). Unlike oral medications that circulate throughout the entire body, this medication is a highly localized Targeted Therapy. It is administered directly into the problem area to break down the hardened scar tissue (plaque) that causes severe penile curvature, providing a non-surgical alternative for men seeking to restore normal anatomical function and sexual health.

• Generic Name: Collagenase Clostridium histolyticum
• US Brand Names: Xiaflex
• Route of Administration: Intralesional injection (injected directly into the plaque)
• FDA Approval Status: Fully FDA-approved for the treatment of adult men with Peyronie’s disease with a palpable plaque and curvature deformity of at least 30 degrees, as well as Dupuytren’s contracture.

What Is It and How Does It Work? (Mechanism of Action)

To understand how Xiaflex works, one must look at the physical changes that occur in Peyronie’s disease. In a healthy state, the tissues of the penis are highly elastic, allowing for normal expansion during an erection. However, in men with Peyronie’s disease, localized trauma or inflammation causes a dense, hardened scar tissue—known as a plaque—to form within the tunica albuginea (the elastic sheath surrounding the erectile tissue). This plaque is made mostly of tough collagen fibers. Because the plaque cannot stretch, the penis bends or curves abnormally during an erection.

Xiaflex functions through targeted proteolytic (protein-breaking) enzyme action. The medication contains two specific collagenases: AUX-I and AUX-II. These enzymes are derived from the bacterium Clostridium histolyticum.

At the molecular level, when Xiaflex is injected directly into the plaque, these two enzymes work together to target and dissolve Types I and III collagen. AUX-I attacks the ends of the collagen fibers, while AUX-II cleaves the internal segments of the fibers. By enzymatically breaking down the tough collagen matrix, the plaque softens and weakens. Following the injection, specialized stretching exercises (penile modeling) help to physically snap the weakened plaque, thereby reducing the curvature and restoring a straighter erection.

FDA-Approved Clinical Indications

Primary Indication

• Peyronie’s Disease: Xiaflex is explicitly FDA-approved for the treatment of adult men with Peyronie’s disease who have a palpable (feelable) plaque and a curvature deformity of at least 30 degrees at the start of therapy.

Other Approved & Off-Label Uses

While primarily used in urology for Peyronie’s disease, its enzyme-breaking properties have other clinical applications:

• Dupuytren’s Contracture: FDA-approved for treating adults with Dupuytren’s contracture with a palpable cord in the hand.
• Primary Urology Indications:
  • Restoration of Reproductive Function: Used to reduce severe penile curvature, making sexual intercourse comfortable and physically possible again.
  • Plaque Disruption: Actively degrades the localized scar tissue that prevents normal expansion of the corpus cavernosum during an erection.

Dosage and Administration Protocols

The administration of Xiaflex is highly specific and must only be performed by a healthcare provider experienced in the treatment of male urological diseases. The treatment is given in “cycles.”

Special Populations and Adjustments:

• Renal and Hepatic Insufficiency: Because Xiaflex is a locally injected enzyme that does not heavily enter the systemic bloodstream, no specific dose adjustments are required for patients with renal impairment (CrCl/GFR) or liver disease.
• Geriatric Patients: No specific dose adjustments are required based on age.
• Administration Rules: After the second injection of a cycle, the healthcare provider will perform a penile modeling procedure to stretch the weakened plaque.

“Dosage must be individualized by a qualified healthcare professional.”

Clinical Efficacy and Research Results

Current clinical research (2020-2026) strongly supports the efficacy of Xiaflex as a frontline Targeted Therapy for Peyronie’s disease. In massive, double-blind clinical trials (such as the IMPRESS trials), patients treated with Xiaflex experienced a highly statistically significant reduction in penile curvature compared to those receiving a placebo.

Precise numerical data indicate that patients typically see an average curvature reduction of 34 percent (roughly a 17-degree improvement). Furthermore, patients report significant improvements in the Peyronie’s Disease Questionnaire (PDQ), specifically noting a sharp decrease in the psychological bother and physical pain associated with the condition.

Unlike systemic oncology treatments such as Androgen Deprivation Therapy, Immunotherapy, or Monoclonal Antibody infusions that impact the entire body, the localized enzymatic action of Xiaflex ensures that systemic markers like PSA nadir or Progression-Free Survival (PFS) in cancer patients remain completely unaffected. It solely focuses on structural urological correction.

Safety Profile and Side Effects

Black Box Warning: Xiaflex carries a severe Black Box Warning for Corporal Rupture (Penile Fracture) or other serious injury to the penis. Because the enzyme weakens tissue, vigorous sexual activity too soon after treatment can cause the penis to fracture. Due to this risk, Xiaflex is only available through a restricted program called the Xiaflex REMS (Risk Evaluation and Mitigation Strategy) Program.

Common Side Effects (>10%)

• Penile Hematoma: Significant bruising at the injection site.
• Penile Swelling: Edema or fluid buildup in the treated area.
• Injection Site Pain: Discomfort, blistering, or tenderness where the needle was inserted.

Serious Adverse Events

• Corporal Rupture (Penile Fracture): A tearing of the tunica albuginea requiring emergency surgical repair.
• Severe Hematoma: Blood pooling that may require medical drainage.
• Hypersensitivity Reactions: Rare allergic reactions, including anaphylaxis.

Management Strategies

To manage bleeding risks, patients must stop all blood thinners and avoid NSAIDs before the procedure. Following injections, a light compression dressing is often applied to manage swelling. The most critical management strategy is strict abstinence from sexual intercourse for at least 4 weeks after the second injection of each cycle.

Research Areas

Active urological research in 2026 is focusing on enhancing the outcomes of Xiaflex by pairing it with mechanical therapies. Clinical trials are investigating the simultaneous use of Xiaflex with penile traction therapy (PTT) or vacuum erection devices (VED) to physically guide the tissue remodeling process and achieve greater curvature reduction.

Furthermore, while Xiaflex is fundamentally a structural enzyme treatment, researchers are exploring its localized delivery mechanisms to see if similar direct-injection strategies could be used for other urological diseases. Although it has no direct connection to gene therapy for bladder cancer or systemic Immunotherapy, the success of intralesional injections is inspiring the development of localized long-acting injectable formulations for managing localized benign urological tumors.

Disclaimer: The research described in the “Research Areas” section for Xiaflex is exploratory in nature and reflects ongoing or hypothetical investigations. These findings are currently not established as standard clinical practice and are not yet applicable to routine professional or therapeutic use. 

Patient Management and Clinical Protocols

Pre-treatment Assessment

• Baseline Diagnostics: A baseline penile ultrasound is strongly recommended to map the exact location of the plaque and ensure it has not calcified (turned to bone), as Xiaflex cannot dissolve calcified plaques.
• Specialized Testing: An artificial erection is often induced in the clinic to precisely measure the degree of curvature using a goniometer.
• Screening: Review of the patient’s medication list is mandatory to ensure they are not on active anticoagulants (blood thinners).

Monitoring and Precautions

• Vigilance: Patients must be closely monitored for a “popping” sound or sudden loss of an erection, which are hallmark signs of corporal rupture.
• Lifestyle and Modeling: Patients must perform gentle, daily penile stretching and modeling exercises at home for 6 weeks following each treatment cycle to maximize the drug’s effectiveness.

“Do’s and Don’ts” List

• DO gently massage and stretch the penis exactly as instructed by your urologist during the 6-week post-treatment period.
• DO apply a cold pack to the injection site to reduce initial swelling and discomfort.
• DO immediately go to the emergency room if you hear a popping sound in your penis accompanied by sudden pain and severe bruising.
• DON’T engage in any sexual intercourse or sexual activity for at least 4 weeks after the second injection of a cycle.
• DON’T take aspirin, ibuprofen, or other blood thinners before your injection without your doctor’s explicit approval.
• DON’T skip your follow-up appointments; penile modeling by your physician is a mandatory part of this therapy.

Legal Disclaimer

The information provided in this comprehensive medical guide is for educational and informational purposes only. It does not replace professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider or specialist Urologist regarding any medical conditions, treatment protocols, or specific medication interactions. Never disregard professional medical advice or delay in seeking it because of something you have read in this material.